Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salem, R.
Right arrow Articles by Lee, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salem, R.
Right arrow Articles by Lee, C
American Journal of Hospital Pharmacy, Vol 38, Issue 3, 354-357
Copyright © 1981 by American Society of Health-System Pharmacists


Articles

Rapid infusion of phenytoin sodium loading doses

RB Salem, BJ Wilder, RL Yost, PL Doering, and C Lee


The use of rapid intravenous infusions of phenytoin sodium to achieve prompt plasma therapeutic concentrations of phenytoin was studied in adult epileptic patients. Six adult patients who experienced recent tonic-clonic seizures were selected for study. Four of them had not been treated with phenytoin before the study; two were on chronic phenytoin therapy but had subtherapeutic serum levels. A leading dose of phenytoin sodium (15 mg/kg in 100 ml of 0.9% sodium chloride injection) was infused at 30-50 mg/min. Blood samples were drawn before phenytoin administration, every five minutes during the infusion, and at 1, 2, 4, 8, 12, 18, and 24 hours after completion of the infusion. Adverse effects were monitored during the infusion. Pharmacokinetic variables were calculated. Patients received from 750 to 1500 mg phenytoin sodium (mean +/- S.D. = 1040.8 +/- 297.3 mg). From 5 to 30 minutes were required to reach therapeutic (10-20 micrograms/ml) serum phenytoin concentrations; concentrations peaked at 31.1 +/- 10.0 micrograms/ml. Four of the six patients had therapeutic serum concentrations at 18 hours after completion of the infusion. Adverse effects were minimal and not severe; no cardiotoxicities were noted. Phenytoin half-life was 31.2 +/- 8.4 hours, total plasma clearance was 47.2 +/- 10.7 ml/kg/hr, and volume of distribution was 1.96 +/- 0.46 liters/kg. It is concluded that rapid intravenous infusion of phenytoin appears to be a reasonably safe and effective method of rapidly reaching therapeutic phenytoin concentrations.
 



This article has been cited by other articles:


Home page
Arch Intern MedHome page
R. F. Spengler, J. B. Arrowsmith, D. J. Kilarski, C. Buchanan, L. Von Behren, and D. R. Graham
Severe Soft-Tissue Injury Following Intravenous Infusion of Phenytoin: Patient and Drug Administration Risk Factors
Arch Intern Med, June 1, 1988; 148(6): 1329 - 1333.
[Abstract] [PDF]


Home page
JAMAHome page
M. P. Earnest, J. A. Marx, and L. R. Drury
Complications of Intravenous Phenytoin for Acute Treatment of Seizures: Recommendations for Usage
JAMA, February 11, 1983; 249(6): 762 - 765.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Society of Health-System Pharmacists.
Advertisement